488 related articles for article (PubMed ID: 32387447)
1. Seroprevalence of antibodies against diphtheria, tetanus, and pertussis among healthy Thai adolescents.
Hanvatananukul P; Prasarakee C; Sarachai S; Aurpibul L; Sintupat K; Khampan R; Saheng J; Sudjaritruk T
Int J Infect Dis; 2020 Jul; 96():422-430. PubMed ID: 32387447
[TBL] [Abstract][Full Text] [Related]
2. Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines recommendations of the Advisory Committee on Immunization Practices (ACIP).
Broder KR; Cortese MM; Iskander JK; Kretsinger K; Slade BA; Brown KH; Mijalski CM; Tiwari T; Weston EJ; Cohn AC; Srivastava PU; Moran JS; Schwartz B; Murphy TV;
MMWR Recomm Rep; 2006 Mar; 55(RR-3):1-34. PubMed ID: 16557217
[TBL] [Abstract][Full Text] [Related]
3. Seroprevalence of Bordetella pertussis antibodies and anti-pertussis antibody response after a single dose of reduced-antigen combined diphtheria, tetanus, and acellular pertussis vaccine (Tdap) in pregnant Thai women.
Sompagdee N; Anuwutnavin S; Phongsamart W; Senawong S; Umrod P; Robkhonburi A
Vaccine; 2020 Mar; 38(12):2725-2733. PubMed ID: 32070680
[TBL] [Abstract][Full Text] [Related]
4. Safety and immunogenicity of SIIPL Tdap, a new tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine, in healthy subjects 4-65 years of age: A Phase II/III randomized, observer-blinded, active controlled, multicenter clinical study in Germany.
Aydin I; May M; Pisano F; Mpofu-Maetzig N; Grode L; Parekh S; Pujari P; Shewale S; Desai S; Sharma H; Rao H; Gautam M; Gairola S; Shaligram U
Vaccine; 2023 Nov; 41(46):6810-6819. PubMed ID: 37827966
[TBL] [Abstract][Full Text] [Related]
5. Reduced-antigen, combined diphtheria, tetanus and acellular pertussis vaccine, adsorbed (Boostrix®): a review of its properties and use as a single-dose booster immunization.
McCormack PL
Drugs; 2012 Sep; 72(13):1765-91. PubMed ID: 22931522
[TBL] [Abstract][Full Text] [Related]
6. Combined, reduced-antigen content tetanus, diphtheria, and acellular pertussis vaccine (Boostrix): a review of its use as a single-dose booster immunization in individuals aged 10-64 years in the US.
Plosker GL
BioDrugs; 2009; 23(4):253-67. PubMed ID: 19697967
[TBL] [Abstract][Full Text] [Related]
7. Vaccination of adults 65 years of age and older with tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Boostrix(®)): results of two randomized trials.
Weston WM; Friedland LR; Wu X; Howe B
Vaccine; 2012 Feb; 30(9):1721-8. PubMed ID: 22212127
[TBL] [Abstract][Full Text] [Related]
8. Acellular pertussis vaccine boosters combined with diphtheria and tetanus toxoid boosters for adolescents: safety and immunogenicity assessment when preceded by different 5-dose DTaP/DTwP schedules.
Pichichero ME; Casey JR; Francis AB; Marsocci SM; Murphy M; Hoeger W; Cleary C
Clin Pediatr (Phila); 2006 Sep; 45(7):613-20. PubMed ID: 16928838
[TBL] [Abstract][Full Text] [Related]
9. Effect of priming with diphtheria and tetanus toxoids combined with whole-cell pertussis vaccine or with acellular pertussis vaccine on the safety and immunogenicity of a booster dose of an acellular pertussis vaccine containing a genetically inactivated pertussis toxin in fifteen- to twenty-one-month-old children. Italian Multicenter Group for the Study of Recombinant Acellular Pertussis Vaccine.
Podda A; Bona G; Canciani G; Pistilli AM; Contu B; Furlan R; Meloni T; Stramare D; Titone L; Rappuoli R
J Pediatr; 1995 Aug; 127(2):238-43. PubMed ID: 7636648
[TBL] [Abstract][Full Text] [Related]
10. A randomised, double-blind, non-inferiority clinical trial on the safety and immunogenicity of a tetanus, diphtheria and monocomponent acellular pertussis (TdaP) vaccine in comparison to a tetanus and diphtheria (Td) vaccine when given as booster vaccinations to healthy adults.
Thierry-Carstensen B; Jordan K; Uhlving HH; Dalby T; Sørensen C; Jensen AM; Heilmann C
Vaccine; 2012 Aug; 30(37):5464-71. PubMed ID: 22776216
[TBL] [Abstract][Full Text] [Related]
11. Seroprevalence of an antibody against diphtheria, tetanus, and pertussis among the elderly in Khon Kaen, Thailand.
Chinchai T; Posuwan N; Vuthitanachot V; Wanlapakorn N; Poovorawan Y
J Health Popul Nutr; 2019 Oct; 38(1):28. PubMed ID: 31627764
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity and safety of a second booster dose of an acellular pertussis vaccine combined with reduced antigen content diphtheria-tetanus toxoids 10 years after a first booster in adolescence: An open, phase III, non-randomized, multi-center study.
Kovac M; Kostanyan L; Mesaros N; Kuriyakose S; Varman M
Hum Vaccin Immunother; 2018; 14(8):1977-1986. PubMed ID: 29630439
[TBL] [Abstract][Full Text] [Related]
13. Levels of antibodies specific to diphtheria toxoid, tetanus toxoid, and Haemophilus influenzae type b in healthy children born to Tdap-vaccinated mothers.
Wanlapakorn N; Maertens K; Thongmee T; Srimuan D; Thatsanathorn T; Van Damme P; Leuridan E; Poovorawan Y
Vaccine; 2020 Oct; 38(44):6914-6921. PubMed ID: 32888740
[TBL] [Abstract][Full Text] [Related]
14. Prevention of pertussis among adolescents: recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine.
America Academy of Pediatrics Commitee on Infectious Diseases
Pediatrics; 2006 Mar; 117(3):965-78. PubMed ID: 16382131
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity and reactogenicity of a Haemophilus influenzae type b tetanus conjugate vaccine when administered separately or mixed with concomitant diphtheria-tetanus-toxoid and acellular pertussis vaccine for primary and for booster immunizations.
Schmitt HJ; Zepp F; Müschenborn S; Sümenicht G; Schuind A; Beutel K; Knuf M; Bock HL; Bogaerts H; Clemens R
Eur J Pediatr; 1998 Mar; 157(3):208-14. PubMed ID: 9537487
[TBL] [Abstract][Full Text] [Related]
16. Safety and immunogenicity of a combined Tetanus, Diphtheria, recombinant acellular Pertussis vaccine (TdaP) in healthy Thai adults.
Sirivichayakul C; Chanthavanich P; Limkittikul K; Siegrist CA; Wijagkanalan W; Chinwangso P; Petre J; Hong Thai P; Chauhan M; Viviani S
Hum Vaccin Immunother; 2017 Jan; 13(1):136-143. PubMed ID: 27686283
[TBL] [Abstract][Full Text] [Related]
17. Prevention of Pertussis, Tetanus, and Diphtheria with Vaccines in the United States: Recommendations of the Advisory Committee on Immunization Practices (ACIP).
Liang JL; Tiwari T; Moro P; Messonnier NE; Reingold A; Sawyer M; Clark TA
MMWR Recomm Rep; 2018 Apr; 67(2):1-44. PubMed ID: 29702631
[TBL] [Abstract][Full Text] [Related]
18. Safety of Diphtheria and Tetanus Toxoids and Acellular Pertussis (DTaP) Vaccine in Adults in Japan.
Ujiie M; Tsuzuki S; Suzuki M; Ota M; Suzuki T; Nomoto H; Yamamoto K; Saito S; Kokaze A; Kinoshita N
Jpn J Infect Dis; 2021 Sep; 74(5):399-404. PubMed ID: 33518629
[TBL] [Abstract][Full Text] [Related]
19. Randomized study of immune responses to two Tdap vaccines among adolescents primed with DTaP and comparison with results among adolescents primed with DTwP.
Decker MD; Greenberg DP; Johnson DR; Pool V
Vaccine; 2019 Aug; 37(35):5003-5008. PubMed ID: 31301919
[TBL] [Abstract][Full Text] [Related]
20. Acellular pertussis vaccine booster combined with diphtheria and tetanus toxoids for adolescents.
Pichichero ME; Blatter MM; Kennedy WA; Hedrick J; Descamps D; Friedland LR
Pediatrics; 2006 Apr; 117(4):1084-93. PubMed ID: 16585302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
